“We achieved a number of critical clinical objectives in 2023,” said Lisa Ricciardi, Cognition’s president and CEO. “We are pleased with the progress being made with our clinical trial partners to advance our Phase 2 studies. In addition, the scientific data generated by our team has continued to provide insights into proteins and biological processes impacted by CT1812 in Alzheimer’s and Parkinson’s diseases as well as dry AMD.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGTX:
- Is CGTX a Buy, Before Earnings?
- Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results
- Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock
- Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock
- Cognition Therapeutics 6.57M share Spot Secondary priced at $1.75
